Five Prime Therapeutics, Inc.
111 Oyster Point Boulevard
About Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) is a publicly traded, clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics to improve the lives of patients with serious diseases. We have an industry-leading and differentiated drug discovery platform. Our comprehensive proprietary libraries of the extracellular proteome, differentiated screening capabilities and protein therapeutic generation and engineering capabilities comprise a unique and powerful IND engine that positions us to discover novel pathways and targets in immuno-oncology and will continue to generate important development programs. Our success with our drug discovery platform has led to a pipeline that is on track to more than double to five development programs in clinical trials across multiple indications in 2018. We also have several undisclosed research programs at different points of the target validation and molecule generation phases that have the potential to yield our next wave of development-stage therapeutic biologics. And we continue to fuel this process at the earliest stages with new screens planned this year.
Five Prime is committed to innovation and outstanding science to develop effective new drugs for the treatment of severe diseases. We value our culture of openness, collaboration and productivity.
The company is in a strong financial position and has an effective executive team and Board of Directors. Discover more about Five Prime at www.fiveprime.com
Stock Symbol: FPRX
Stock Exchange: Nasdaq
Come take a look inside Five Prime Therapeutics and hear what our employees are saying about our culture and why they joined our company
199 articles with Five Prime Therapeutics, Inc.
Five Prime Therapeutics Announces Collaboration with Roche to Develop Companion Diagnostics for Targeted Immuno-Oncology Investigational Drug Candidates
Five Prime Therapeutics, Inc. announced it has entered into a collaboration with Roche to develop immunohistochemistry (IHC) companion diagnostic assays for use with Five Prime’s first-in-class investigational drug candidates.
Five Prime Therapeutics, Inc. will join the Pancreatic Cancer Action Network (PanCAN) PurpleStride San Francisco.
There have been a number of leadership changes in the life sciences industries over the past week. BioSpace compiled a roundup of the changing landscape of the c-suite and boards of directors across the industry.
After a two-year wait, AstraZeneca finally has employees under one roof in the Bay Area.
Cabiralizumab advanced into a randomized Phase 2 trial in pancreatic cancer
Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Trial of Novel First-in-Class B7-H4 Antibody FPA150
Five Prime Therapeutics, Inc. announced that it initiated patient dosing in its Phase 1 clinical trial of FPA150, a first-in-class immuno-oncology antibody that targets B7-H4.
Five Prime Therapeutics Licenses New Target to UCB Originating from its Proprietary Protein Discovery Platform
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced UCB has elected to exclusively license an undisclosed drug target for inflammatory diseases.
Five Prime Therapeutics, Inc. announced that Marc Belsky, Senior Vice President and Chief Financial Officer, has resigned to pursue another opportunity.
Five Prime Therapeutics, Inc. provided a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2017.
Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 27
The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Leerink Partners LLC are acting as book-running managers for the offering.
Five Prime Therapeutics Announces $25M Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone
Initiation of Phase 2 study of Cabiralizumab plus Opdivo in advanced pancreatic cancer.
The offering is expected to close on January 29, 2018, subject to customary closing conditions.
Five Prime intends to grant the underwriters in the offering a 30-day option to purchase up to an additional 15% of these shares of common stock offered in the public offering.
Five Prime Therapeutics Submits Investigational New Drug Application for Novel B7-H4 Antibody FPA150
Dual mechanism of action blocks a T cell checkpoint pathway and delivers enhanced ADCC against B7-H4-expressing tumor cells
Five Prime Therapeutics Initiates Patient Dosing in Phase I Lead-In to Phase 3, Global Registrational Trial of FPA144 in Front-Line Advanced Gastric Cancer
The open label Phase 1 portion of the trial will evaluate ascending doses of FPA144 in combination with the modified FOLFOX6 regimen (mFOLFOX6) to identify a recommended dose for Phase 3.
Five Prime and Zai Lab today announced an exclusive license agreement for FPA144 in Greater China and global strategic development collaboration.
Five Prime Therapeutics Presents Poster on FGFR2b Expression and Immune Signature in Urothelial Cancer at the Society for Immunotherapy of Cancer 32nd Annual Meeting
Five Prime is developing FPA144, an isoform-selective antibody, as a targeted immunotherapy for tumors that overexpress FGFR2b.
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (Anti-CSF-1 Receptor Antibody) With Opdivo (nivolumab) in Patients With Advanced Solid Tumors
Preliminary results show that the safety profile of cabiralizumab plus Opdivo was generally consistent with that of Opdivo monotherapy, and that the combination results in dose-related decreases in circulating monocytes.
Five Prime stock took a beating after it unintentionally released Phase Ia/Ib clinical trial of its CSF-1R antibody cabiralizumab with BMS' Opdivo (nivolumab).